What is it about?
We aimed to evaluate the impact on overall survival of gastrectomy in asymptomatic metastatic esophago-gastric cancer. Five hundred and thirteen patients were included in the analysis. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. Multivariate analysis confirmed that gastrectomy was a predictor of longer overall survival, as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery.
Featured Image
Why is it important?
Surgery may play a role in increasing survival of patients with metastatic disease who receive active systemic chemotherapy.
Perspectives
Ongoing trials will definitively answer the question whether palliative surgery on primary tumor may be of benefit for metastatic gastric and gastro-esophageal junction cancer patients who respond to first-line chemotherapy.
Lorenzo Fornaro
Azienda Ospedaliero-Universitaria Pisana
Read the Original
This page is a summary of: Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough, Future Oncology, October 2017, Future Medicine,
DOI: 10.2217/fon-2017-0246.
You can read the full text:
Resources
Contributors
The following have contributed to this page
